LAW vs LEGN vs LFST vs FATE

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

5% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). LifeStance Health Group, Inc. (LFST) offers the better valuation at 384. 8x trailing P/E (102. 7x forward), making it the more compelling value choice. Analysts rate Legend Biotech Corporation (LEGN) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, LifeStance Health Group, Inc.

is actually cheaper at 102. 7x.

Over the past 5 years, Legend Biotech Corporation (LEGN) delivered a total return of -4.

2%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: FATE returned +38. 2% versus LAW's -90. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CS Disco, Inc.

(LAW) is the lower-risk stock at 0. 67β versus Fate Therapeutics, Inc. 's 1. 99β — meaning FATE is approximately 195% more volatile than LAW relative to the S&P 500. On balance sheet safety, LifeStance Health Group, Inc. (LFST) carries a lower debt/equity ratio of 13% versus 41% for Legend Biotech Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

5% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: LifeStance Health Group, Inc. grew EPS 113. 3% year-over-year, compared to -66. 0% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LifeStance Health Group, Inc.

(LFST) is the more profitable company, earning 0. 7% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LFST leads at 1. 8% versus -22. 2% for FATE. At the gross margin level — before operating expenses — LAW leads at 74. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, LifeStance Health Group, Inc.

(LFST) trades at 102. 7x forward P/E versus 116. 2x for Legend Biotech Corporation — 13. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FATE: 1552. 7% to $39. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, CS Disco, Inc.

(LAW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 67)). Fate Therapeutics, Inc. (FATE) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LAW: -90. 0%, FATE: +38. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LAW (Technology) and LEGN (Healthcare) and LFST (Healthcare) and FATE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LAW is a small-cap quality compounder stock; LEGN is a small-cap high-growth stock; LFST is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.